Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta

Jane F. Apperley, Martine Gardembas, Junia V. Melo, +16

New England Journal of Medicine

Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia

Kate Stringaris, Takuya Sekine, A. Khoder, +13

Haematologica

Mixed-phenotype Acute LeukemiaInnate Immune SystemImmunologyImmune RegulationFunctional Defects +18

BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships

Jamshid S. Khorashad, Todd W. Kelley, Philippe Szankasi, +19

Blood

Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis

Fabrizio Vianello, Federica Villanova, Veronica Tisato, +8

Haematologica

Allogeneic BK Virus–Specific T Cells for Progressive Multifocal Leukoencephalopathy

Muharrem Müftüoğlu, Amanda Olson, David Marin, +9

New England Journal of Medicine

ImmunologyPathologyImmunotherapyFirst InfusionHematology +16

Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation

Aristeidis Chaidos, Scott D. Patterson, Richard Szydlo, +14

Blood

The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib

Jamshid S. Khorashad, Mona Anand, David Marin, +8

Leukemia

Hematological MalignancyClinical ResistanceHealth SciencesMedicineBcr-abl Mutant Allele +7

Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy

Jaspal Kaeda, Derville O’Shea, Richard Szydlo, +8

Blood

Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia

Dragana Milojković, Emma Nicholson, Jane F. Apperley, +13

Haematologica

Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse

David Marin, Jaspal Kaeda, Richard Szydlo, +11

Leukemia

Chronic PhaseChromatinHematological MalignancyMedicineMixed-phenotype Acute Leukemia +9